Biocon

The Competition Commission of India (CCI) has approved a proposed deal involving Serum Institute Life Sciences, Covidshield Technologies and Biocon Biologics. Once the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to the notice filed with the regulator. Covidshield Technologies Pvt Ltd (CTPL), a wholly-owned subsidiary of Serum Institute of Life Sciences, will be merged into Biocon Biologics. In a tweet on Wednesday, the watchdog said it has cleared the "merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for acquisition of approximately 15 per cent equity shareholding of Biocon Biologics by Serum Institute Life Sciences." CTPL was incorporated to undertake the business of marketing, selling and distributing vaccines, drugs and other pharmaceutical products. Biocon Biologics Ltd is a subsidiary of Biocon Ltd. It offers treatment for chronic and acute diseases such as

Stocks to Watch: The US markets suffered the biggest one-day sell-off in almost two years -Investors worry about inflation and its impact on earnings and prospects for monetary policy tightening

Biocon Biologics is a subsidiary of Biocon Ltd

The BJP used the signing of MoU for setting up the largest semiconductor fabrication unit in Karnataka to hit out at Shaw

Biocon's consolidated revenue from operations in the fourth quarter stood at Rs 2,408.8 crore as against Rs 1,842.1 crore in the year-ago period

As of 06:50 AM, the SGX Nifty April futures quoted at 17,066. According to analysts, the April series has been one of the most volatile series for the Nifty in recent times. The options data.

The BJP accused her of imposing personal and 'politically coloured' opinion and conflating it with India's leadership in Information technology and biotechnology sectors

Mazumdar-Shaw, who is also the Executive Chairperson of Biocon Biologics, will be joining RSE's current fellowship of around 1,700 fellows, the company said in a statement

Biocon arm buys Viatris biosimilars biz for $3.2 billion

The company in a statement said that its subsidiary Biocon Biologics has inked a pact to acquire Viatris Inc's biosimilars business for consideration of up to USD 3.335 billion

Closing Bell: Hindalco (up over 7 per cent), Tata Steel, Power Grid, JSW Steel, Coal India, BPCL, Titan Company, RIL, and Indian Oil Corporation were the biggest large-cap gainers on the bourses today

The companies will also enter into a transition services agreement. Viatris will provide certain transition services, including commercialization services for an expected 2-years

BBL will also obtain Viatris' rights in all biosimilars assets, including its in-licensed portfolio and an option to acquire Viatris' rights in bAflibercept

Industry leaders on Saturday paid rich tributes to noted industrialist Rahul Bajaj (83) who passed away due to illness at his home in Pune. Taking to Twitter, Mahindra Group Chairman Anand Mahindra stated: I stand on the shoulders of giants. Thank you, Rahulbhai, for letting me clamber up onto your broad shoulders, advising me, cheering me on, encouraging me to be bold. Your footprints on the sands of Indian Business will never be extinguished." Biocon Executive Chairperson Kiran Mazumdar-Shaw tweeted: "Industrialist Rahul Bajaj, Former Chairman Of Bajaj Group, Dies At 83 - I am devastated - he was a dear dear friend and will miss him dearly. The country has lost a great son & nation builder." TVS Motor Company Chairman Venu Srinivasan stated that Bajaj strode across the Indian industrial landscape like a colossus. "He was among the few stars who created the Indian automotive industry. He was a pioneer who established a culture of quality and technology. He stood for high ...

Biocon said its subsidiary Biocon Pharma has received approval of its ANDA for Posaconazole Delayed-Release tablets from the US FDA.

In a Q&A, Dr Arun Chandavarkar spoke on how its interchangeable insulin biosimilar has driven the business

Notwithstanding the muted broader market trend, shares of Biocon Ltd surged over 3 per cent on Friday after the biotechnology major reported strong December quarter earnings. On BSE, the stock opened at Rs 363, then touched a high of Rs 382.45, registering a gain of 5.09 per cent over its last close. The stock finally ended at Rs 376.60, up 3.49 per cent. In a similar trend on NSE, the stock opened at Rs 364.00, then jumped 5.02 per cent and touched an early high of Rs 382.50 in initial deals. It finally settled at Rs 376.45, up 3.36 per cent. On Thursday, biotechnology major Biocon Ltd reported a 17.68 per cent rise in consolidated net profit at Rs 219.6 crore for the third quarter ended December 31, 2021. The company had posted a consolidated net profit of Rs 186.6 crore in the same quarter of the previous fiscal. Consolidated total income in the third quarter this fiscal stood at Rs 2,222.5 crore, compared to Rs 1,885.3 crore a year ago. The biosimilars vertical clocked revenue

Bandhan Bank, HDFC Life, Hindustan Zinc, Voda Idea, Inox Leisure, JSW Steel, Kajaria Ceramics, L&T Fin Holdings, PVR, Reliance Industries, SBI Life and Supriya Lifescience to announce results today

Biosimilars vertical clocked revenue of Rs 981.4 crore as compared to Rs 768.9 crore in the same quarter last fiscal

Analysts, however, expect markets to recover from here on as they have reached their key support zones.